An engineered IgG induces degradation of endogenous IgG, providing a potential therapeutic approach to autoimmune disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vaccaro, C. et al. Nat. Biotechnol. 23, 1283–1288 (2005).
Junghans, R.P. Immunol. Res. 16, 29–57 (1997).
Martin, W.L., West, A.P. Jr., Gan, L. & Bjorkman, P.J. Molec. Cell. 7, 867–877 (2001).
Bitonti, A.J. et al. Proc. Natl. Acad. Sci. USA 101, 9763–9768 (2004).
Hinton, P.R. et al. J. Biol. Chem. 279, 6213–6216 (2004).
Akilesh, S. et al. J. Clin. Invest. 113, 1328–1333 (2004).
Liu, Z. et al. J. Exp. Med. 186, 777–783 (1997).
Jin, F. & Balthasar, J.P. Hum. Immunol. 66, 403–410 (2005).
Dall' Acqua, W.F. et al. J. Immunol. 169, 5171–5180 (2002).
Ghetie, V. et al. Nat. Biotechnol. 15, 637–640 (1997).
Samuelsson, A., Towers, T.L. & Ravetch, J.V. Science 291, 484–486 (2001).
Getman, K.E. & Balthasar, J.P. J. Pharm. Sci. 94, 718–729 (2005).
Roopenian, D.C. et al. J. Immunol. 170, 3528–3533 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blumberg, R., Lencer, W. Antibodies in the breakdown lane. Nat Biotechnol 23, 1232–1234 (2005). https://doi.org/10.1038/nbt1005-1232
Issue Date:
DOI: https://doi.org/10.1038/nbt1005-1232